CLB · Core Laboratories Inc. /DE/
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Diluted earnings per share, ex-items non-GAAP | $0.17 | Six Months Ended June 30, 2026 | — |
|
|
|||
| Production Enhancement operating margins, ex-items non-GAAP | 12% | Q2 2026 | — |
|
|
|||
| ROIC non-GAAP | 8.3% | Q2 2026 | — |
| Shares of common stock repurchased | 214,712 | Q2 2026 | — |
|
|
|||
| Free cash flow | $0.5M | first quarter of 2026 | — |
|
|
|||
| Net debt increase | $3.9M | first quarter of 2026 | — |
| Operating income, ex-items non-GAAP | $6.6M | first quarter of 2026 | — |
|
|
|||
| Operating margin, ex-items (Reservoir Description) non-GAAP | 6% | first quarter of 2026 | — |
| Leverage ratio | 1.09 | Q4 2025 | — |
| Reservoir Description incremental margins non-GAAP | 27% | Q4 2025 | — |
| Reservoir Description operating margins, ex-items non-GAAP | 14% | Q4 2025 | — |
| Shares repurchased | 363,207 | Q4 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Oil & Gas Equipment & Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLB
this stock
Core Laboratories Inc. /DE/
|
$577.92M | -23.3% | +0.5% | 24.2 | 9.1% |
|
SLB
Slb Limited/Nv
|
$79.57B | +39.5% | +9.5% | 26.2 | 3.8% |
|
BKR
Baker Hughes Co
|
$63.97B | +37.9% | -0.3% | — | 2.5% |
|
FTI
TechnipFMC plc
|
$30.20B | +74.2% | +9.4% | 26.8 | 3.4% |
|
HAL
Halliburton Co
|
$29.18B | +26.3% | +22.5% | — | 4.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLB | -0.8% | +4.2% | -30.1% | +15.5% | -23.3% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +1.2% | +0.8% | -41.3% | +13.4% | -35.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.